Business Responsibility and Sustainabilty Report for the Financial Year 2025-26

Date: August 3, 2026 To, To, The Manager, The Manager Lis�ng Department, Lis�ng Department BSE Limited Na�onal Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor, Plot no. C/1, Block Dalal Street – Fort Bandra Kurla Complex, Bandra (East), Mumbai 400001 Mumbai 400051 Scrip Code: 544578 N S E S y m b o l : R U B I C O N ISIN- INE506V01022 Sub: Business Responsibility and Sustainability Report for the financial year 2025-26 Dear Sir/Madam, Pursuant to Regula�on 34 of the SEBI (Lis�ng Obliga�ons and Disclosure Requirements) Regula�ons, 2015, we are enclosing herewith the Business Responsibility and Sustainability Report for the financial year 2025-26, which also forms part of the Integrated Annual Report for the financial year 2025-26. The Report is also available on the website of the Company at www.rubicon.co.in. You are requested to take the above informa�on on record. Thanking you, Yours faithfully, For Rubicon Research Limited (Formerly known as Rubicon Research Private Limited) Deepashree Tanksale Company Secretary and Compliance Officer M. No.: A28132 Encl.: As Above Rubicon Research Limited (formerly known as Rubicon Research Private Limited) | CIN: L73100MH1999PLC119744 Registered Office: Plot No. B-75, MedOne House, Road No. 33, Wagle Estate, Thane West, PIN – 400 604, Maharashtra, India �� +91-22-61414000 / 50414000 | ����� reachus@rubicon.co.in | � www.rubicon.co.in Business Responsibility and Sustainability Report SECTION A: GENERAL DISCLOSURES I. Details of listed entity 1. Corporate Identity Number (CIN) of the Company L73100MH1999PLC119744 2. Name of the Company Rubicon Research Limited (‘Company’) 3. Year of Incorporation 1999 4. Registered Office Address MedOne House, B-75, Road No. 33, Wagle Estate, 5. Corporate Address Thane - 400 604 6. Email Address rubicon@rubicon.co.in 7. Telephone 91-22-61414000/50414000 8. Website www.rubicon.co.in 9. Financial Year Reported 2025-26 10. Name of the Stock Exchanges where shares are listed The BSE Limited & The National Stock Exchange of India Limited 11. Paid-up Capital 16,50,92,124 12. Name and contact details (telephone, email address) of the Name – Ms. Deepashree Tanksale person who may be contacted in case of any queries on the Designation – Company Secretary BRSR report Telephone Number – +91 022 65435800 Email ID – secretarial@rubicon.co.in 13. Reporting boundary - Are the disclosures under this report Standalone made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together). 14. Name of assurance provider Not Applicable (NA) 15. Type of assurance obtained NA II. Products/Services 16. Details of business activities (accounting for 90% of the turnover) Sl. Description of Main % of turnover of Description of Business Activity No. Activity the Company 1 Pharmaceuticals Company is into pharmaceutical formulations driven by innovation through 100% focused research and development delivering value to customers and investors by developing, manufacturing and marketing branded specialty and generic pharmaceutical products. 17. Products/Services sold by the Company (accounting for 90% of the turnover) Product/Service NIC Code % of total turnover contributed 1 Pharmaceutical Products 21002 100% Rubicon Research Limited Integrated Annual Report 2025-26 III. Operations 18. Number of locations where plants and/or operations/offices of the Company are situated: Location Number of plants Number of offices Total National 3 2 5 International 0 7 7 19. Markets served by the Company a. Number of locations Locations Number National (No. of States) 3 International (No. of Countries) 8 b. What is the contribution of exports as a percentage of the total turnover of the Company? 98.44% c. Types of customers Company markets branded and generic prescription pharmaceutical products, primarily in the United States, through its subsidiaries, Validus and AdvaGen Pharma as well as third-party sales and marketing entities. Company serves wholesalers, major pharmacy chains, group purchasing organizations (GPOs), regional and national pharmacy networks and Managed Care Organizations. IV. Employees 20. Details as at the end of Financial Year a. Employees and workers (including differently abled): S. Male Female Particulars Total (A) No. No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1. Permanent (D) 1,290 1,073 83.18% 217 16.82% 2. Other than Permanent (E) 13 7 53.85% 6 46.15% 3. Total employees (D + E) 1,303 1,080 82.89% 223 17.11% WORKERS 4. Permanent (F) 0 0 0.00% 0 0.00% 5. Other than Permanent (G) 582 558 95.88% 24 4.12% 6. Total workers (F + G) 582 558 95.88% 24 4.12% b. Differently abled Employees and workers: S. Male Female Particulars Total (A) No. No. (B) % (B / A) No. (C) % (C / A) EMPLOYEES 1. Permanent (D) 0 0 0 0 0 2. Other than Permanent (E) 0 0 0 0 0 3. Total employees (D + E) 0 0 0 0 0 WORKERS 4. Permanent (F) 0 0 0 0 0 5. Other than Permanent (G) 0 0 0 0 0 6. Total workers (F + G) 0 0 0 0 0 21. Participation/Inclusion/Representation of Women No. and percentage of Females Particulars Total (A) No. (B) % (B / A) Board of Directors 8 2 25% Key Management Personnel 2 1 50% 22. Turnover rate for permanent employees and workers (disclose trends for the past 3 years) FY 2025-26 FY 2024-25 FY 2023-24 Male Female Total Male Female Total Male Female Total Permanent Employees 19.27% 21.95% 19.74% 25.55% 19.19% 24.39% 23.38% 26.52% 23.97% Permanent Workers 0 0 0 0 0 0 0 0 0 V. Holding, Subsidiary and Associate Companies (including joint ventures) 23. Name of holding/subsidiary/associate companies/joint ventures Does the entity indicated at Column A, Name of the Holding/ Subsidiary/ participate in Sl. Indicate whether Holding/ % of shares held by Associate Companies/Joint Ventures the Business No. Subsidiary/Associate/Joint Venture the Company (A) Responsibility initiatives of the Company (Yes/ No) 1 Advagen Holdings Inc Subsidiary 100% No 2 AdvaGen Pharma Limited Subsidiary 100% No 3 AIM RX3PL LLC* Subsidiary 100% No 4 Validus Pharmaceuticals LLC* Subsidiary 100% No 5 Kinaxon Bio Inc (formerly Advatech Subsidiary 100% No Bio Pharma Ltd) 6 Advagen Pharma Europe OÜ Subsidiary 100% No 7 Rubicon Research Australia Pty Ltd Subsidiary 100% No 8 KIA Health Tech Private Limited Subsidiary 100% No 9 Rubicon Consumer Healthcare Private Subsidiary 100% No Limited 10 Rubicon Academy LLP* Subsidiary 98.04% No 11 Rubicon Research Canada Limited Subsidiary 100% No 12 Rubicon Research Private Limited Subsidiary 100% No (Singapore) 13 AdvaGen S A Company Subsidiary ** No *Investment by the Company is considered as equity contribution. ** Control exists by virtue of control over composition of Board of Directors VI. CSR Details 24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes (ii) Turnover (in H): H 13,060.82 Million (iii) Net worth (in H): H 13,209.83 Million Rubicon Research Limited Integrated Annual Report 2025-26 VII. Transparency and Disclosure Compliances 25. Complaints/Grievances on any of the principles (Principle 1 to 9) under the National Guidelines on Responsible Business Conduct: FY 2025-26 FY 2024-25 Grievance Redressal Stakeholder No. of No. of Mechanism in place group from No. of complaints No. of complaints (Yes/No) whom complaints pending complaints pending (If yes, then provide Remarks Remarks compliant is filed during resolution at filed during resolution at web link for grievance received the year close of the the year close of the redressal policy) year year Communities Yes Nil Nil No Nil Nil No complaints complaints received received Investors Yes Nil Nil No Nil Nil No (other than complaints complaints shareholders) received received Shareholders Yes 18 0 All Nil Nil No shareholders complaints complaints received have closed Employees Yes Nil Nil No Nil Nil No and workers complaints complaints received received C [Showing first 8,000 characters — download PDF for full document]